ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

MSK, Fox Chase Volunteer to Limit Their Core Grants To Let Others Grow

June 29, 1990

The Donald Pinkel Archive

May 21, 2021

Congressional Panel Is Investigating FDA Oversight Of Generic Cancer Drugs

August 18, 1995

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

NIH Awards 24 More Grants For Women’s Health Initiative

October 14, 1994

ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies

June 22, 2012